#South Korea #Seoul #preclinical CRO #CorestemChemon #ATG Lifetech

CorestemChemon Partners with ATG Lifetech to Elevate Preclinical Services

CorestemChemon, a top-tier GLP-certified preclinical contract research organization (CRO) based in South Korea, has officially announced its strategic partnership with ATG Lifetech. This collaboration marks a significant move in the biotech landscape, aiming to revolutionize non-clinical solutions tailored for pharmaceutical and biotech companies across the US, Europe, and Asia.

Advancing Preclinical Testing

The alliance between CorestemChemon and ATG Lifetech is focused on co-developing innovative platforms that emphasize precision and efficiency within preclinical drug development. Both companies are set to introduce:

• - A transcriptome-based evaluation platform for a thorough analysis of drug efficacy and safety.
• - Organoid models that are disease-relevant and relevant to the liver, heart, and blood-brain barrier (BBB).
• - A high-throughput analytics service that will distinguish between true and false positives in tumorigenicity studies.
• - Shared insights regarding regulatory compliance, thus supporting clients aiming for FDA or EMA approvals.

According to a spokesperson from CorestemChemon, the integration of ATG Lifetech's leading technologies will significantly enhance their preclinical services, positioning CorestemChemon as a formidable player in the global CRO market. The spokesperson stated, "ATG Lifetech's innovative transcriptome and organoid platforms will elevate the scientific rigor of our services, enabling us to meet and exceed the demands of our clients."

The Importance of Organoid-Based Models

Organoid-based assays are receiving heightened recognition for their potential to offer greater predictive accuracy—up to five times more effective than traditional 2D cell cultures—when it comes to toxicity and efficacy screening. By merging this innovative methodology with whole-transcriptome analysis, clients will benefit from quicker decision-making processes in drug pipelines. This comprehensive approach aids in minimizing risks when entering clinical trials and helps in shortening overall development timelines.

Strategic Growth and Future Outlook

Investors should take note that this partnership underpins CorestemChemon's strategy to scale up its high-margin, intellectual property-driven CRO services on a global scale. Revenue-generating service offerings are projected to launch by late 2025, with substantial global demand already on the horizon.

ATG Lifetech enhances this partnership by bringing validated experience from its global collaborations, including with renowned firms like ACROBiosystems in Switzerland. The company has also been integral to several biopharma initiatives backed by the South Korean government.

The two companies are planning to present their joint research developments at a prominent conference focused on toxicology and preclinical science in the fourth quarter of 2025. Following that, global service launches are expected to cater specifically to biotechnology and pharmaceutical clients requiring high-fidelity preclinical testing.

CorestemChemon (KOSDAQ: 166480) has been in the field of preclinical research for over 20 years, offering proficiency in GLP-based toxicology, pharmacokinetics, and regulatory compliance. The company operates multiple AAALAC-certified facilities and collaborates with leading biopharmaceutical innovators across Asia, the U.S., and Europe, positioning itself as an essential partner in advancing biomedical research.